ARCHIVES

ODAC To Advise FDA on First Biosimilars Application Jan. 7

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Advisors Criticize Plan To Fund R01s On ESA Research With Amgen, J&J Money.

June 27, 2008

President’s Budget Asks $1.646 Billion for NCI In FY 1990, Including AIDS, 3% Increase Over ‘89

January 13, 1989

ACS names new officers.

December 5, 2003

Diet/Nutrition Advisory Group Blast Fund Limit, Incurs Schmidt Wrath

February 4, 1977

President Calls For Reversing Cuts to Basic Research Budget

January 31, 2014

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012